In the trial, NBTXR3 will be given to the patients before surgery by a single intra-tumoral injection followed by standard radiotherapy procedure.
The primary endpoints of the clinical trial are the feasibility of NBTXR3 administration and safety.
Nanobiotix CEO and co-founder Laurent Levy said developed in close collaboration with leading oncologists and radiotherapists, NBTXR3 is the first product from their NanoXray pipeline to enter clinical development.